LGC announces changes to its Executive Leadership Team

News (ZH) - These changes follow recent strong trading performance and further strategy endorsement by Cinven and Astorg, LGC’s new shareholders.

LGC acquires The Native Antigen Company, strengthening its offer to the IVD sector

News (ZH) - Acquisition strengthens LGC’s existing product offering to IVD sector, which includes quality assurance tools, immunoassay reagents and disease state plasma 

LGC expands SARS-CoV-2 molecular solutions to full genome coverage

News (ZH) - Expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining safety features

LGC SeraCare SARS-CoV-2 Molecular Controls Kit now CE-Marked

News (ZH) - Bearing the CE mark and IVD symbol signifies that the AccuPlex SARS-CoV-2 Molecular Controls Kit meets extensive design control requirements

LGC releases SARS-CoV-2 & influenza multiplexed molecular quality solutions

News (ZH) - Kit designed to measure day-to-day performance of the assay providing positive and negative reference solution

LGC signs pre-let for new R&D facility at Oxford Technology Park

News (ZH) - Site will accommodate mixture of bespoke laboratory, office and logistics operations

LGC's Anti-SARS-CoV-2 controls kit now CE Marked

News (ZH) - CE mark and IVD symbol signifies that ACCURUN Anti-SARS-CoV-2 Controls Kit meets extensive design control requirements

LGC launches SARS-CoV-2 molecular solution for Oral Fluid Testing

News (ZH) - Product designed to support development and testing efforts around novel saliva-based SARS-CoV-2 diagnostics

LGC acquires Technopath Clinical Diagnostics, strengthening its position in clinical quality controls

News (ZH) - Complements a wide breadth of existing manufacturing capabilities